Merck & Co MRK

Mr. Davis, Merck's Chairman, Chief Executive Officer, and President, has extensive management, financial, and operational expertise. Previously, Mr. Davis served as Merck's President, with responsibility for Merck's operating divisions, Human Health, Animal Health, Manufacturing, and Merck Research Laboratories. Prior to that, he served as Merck's Chief Financial Officer and Executive Vice President, Global Services, with broad responsibilities, including with respect to finance, risk management, real estate operations, corporate strategy, business development, information technology, and procurement. In addition, Mr. Davis's service on the board of directors of Duke Energy, including his roles as Chair of the Finance & Risk Management Committee and member of the Corporate Governance Committee, has provided him with valuable experience on governance issues facing public companies. Career Highlights Merck & Co., Inc. ; Chairman (2022-present) ; Chief Executive Officer and President (2021-present) ; Chief Financial Officer and Executive Vice President, Global Services (2016-2021) ; Chief Financial Officer and Executive Vice President (2014-2016) Baxter International, Inc. ; Corporate Vice President and President, Medical Products (2010-2014) ; Corporate Vice President and Chief Financial Officer (2006-2010) ; Corporate Vice President and Treasurer (2004-2006) Other Public Directorships Current ; Duke Energy (2018-present) Former ; C.R. Bard (2015-2017).

Mr. Dean Y. Li, President, Executive Vice President, President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2021).

Ms. Caroline Litchfield, Executive Vice President and Chief Financial Officer (since April 2021); Senior Vice President, Corporate Treasurer (January 2018-March 2021).

Ms. Jennifer Zachary, Executive Vice President, General Counsel and Corporate Secretary (since January 2020); Executive Vice President and General Counsel (April 2018-January 2020); Prior to that, Partner, Covington & Burling LLP.

Mr. Glocer has extensive management, operational, technology, and international business expertise. This includes Mr. Glocer's history of accomplishment and executive ability as CEO and a Director of Thomson Reuters Corporation, a news and information provider for businesses and professionals. In addition, his directorships at other public companies, including his service as Lead Director and as a member of the Governance Committee at Morgan Stanley, provide him with valuable experience on governance issues facing public companies. Career Highlights Angelic Ventures LP, a family office investing in early-stage technology and data companies; Founder and Managing Partner (2012-present) Thomson Reuters Corporation, multi-national media and information firm; Chief Executive Officer (2008-2011) ; Chief Executive Officer, Reuters Group PLC (2001-2008) Other Public Directorships Current; Morgan Stanley (2013-present); Publicis Groupe (2016-present).

Mr. Karsanbhai has broad experience in global business leadership as President and Chief Executive Officer of Emerson Electric Co., a global technology and software company that provides innovative solutions for customers in a wide range of markets around the world. Mr. Karsanbhai has extensive expertise in strategy, technologies, manufacturing, and business development in diverse markets globally, as evident in varied leadership positions he has held since joining Emerson in 1995. These positions include lead for Emerson's Automation Solutions business, where he elevated Emerson's software profile and digital transformation business, and President of Emerson's Rosemount business. In addition, Mr. Karsanbhai currently serves as the Chair of the Federal Reserve Bank of St. Louis and is a Trustee of Washington University. He is fluent in Portuguese, French, and English, and has lived and worked in Europe, Africa, and North America. Career Highlights: Emerson Electric Co., President and Chief Executive Officer (2021-present), Executive President, Emerson Automation Solutions (2018-2021). Other Public Directorships: Current: ?Emerson Electric Co. (2021-present).

Dr. Seidman has extensive scientific experience relevant to the biopharmaceutical industry. She also has managerial experience relevant to scientific research, including through her role leading the Seidman Laboratory, a research laboratory focusing on integrating clinical medicine and molecular technologies to define disease-causing gene mutations and genetic variations that increase disease risk. The recipient of many honors, Dr. Seidman was elected to the American Society for Clinical Investigation, the National Academy of Sciences, American Academy of Arts and Sciences, and the National Academy of Medicine. Awards ; The Ray C. Fish Award for Scientific Achievement (2020) ; American Heart Association Medal for Genomic and Precision Medicine (2019) ; Vanderbilt Prize in Biomedical Sciences (2019) Career Highlights Harvard Medical School/Brigham and Women's Hospital (Harvard University) ; Thomas W. Smith Professor of Medicine and Genetics (2005-present) ; Professor of Genetics and Medicine (1998-2005) ; Professor of Medicine (1997-1998) Howard Hughes Medical Institute, non-profit medical research organization ; Investigator (1994-present) Brigham and Women's Hospital ; Director, Cardiovascular Genetics Center (1992-present) ; Attending Physician, Cardiovascular Division (1987-present).

Ms. Russo has extensive management, operational, international business and financial expertise, as well as a broad understanding of the technology industry, which includes her career achievements during her tenure as CEO and Director of Alcatel-Lucent and Lucent Technologies Inc. In addition, her directorships at other public companies, including her roles as the Non-executive Chair of Hewlett Packard Enterprise Company and Chair of the Governance and Corporate Responsibility Committee of General Motors, provide her with deep experience on governance issues facing large public companies. Career Highlights Hewlett Packard Enterprise Company, technology company ; Non-executive Chair (2015-present) Alcatel-Lucent, global telecommunications equipment company ; Chief Executive Officer and Director (2006-2008) ; Chairman, Lucent Technologies Inc. (2003-2006) ; President and Chief Executive Officer, Lucent Technologies Inc. (2002-2006) Other Public Directorships Current ; General Motors Company (2009-present), Independent Lead Director (2010-2014; 2021-present) ; Hewlett Packard Enterprise Company (2015-present), Non-executive Chair (2015-present) ; KKR Management Inc. (the managing partner of KKR & Co., L.P.) (2011-present) Former ; Arconic, Inc. (2016-2018) formerly Alcoa, Inc. (2008-2016).

Mr. Baker has wide-ranging expertise in corporate governance and general and organizational management, including a deep understanding of global marketing, sales, and operations of public companies. Mr. Baker is a Founding Partner of E2SG Partners, a company that invests in environmentally sustainable technologies. Previously, Mr. Baker was Chairman & Chief Executive Officer of Ecolab Inc., a provider of water and hygiene services and technologies for the food, hospitality, industrial, and energy markets. Mr. Baker is also a member of the Board of Target Corporation and served as their Lead Independent Director from 2015 to 2021. This directorship as well as his previous directorship at U.S. Bancorp provide him with deep experience on governance issues facing large public companies. Career Highlights: E2SG Partners ; Founding Partner (2022-present) Ecolab Inc. ; Executive Chairman (2021-2022) ; Chairman and Chief Executive Officer (2006-2020) ; Chief Executive Officer (2004-2006). Other Public Directorships: Current ; Target Corporation (2013-present) Former ; Ecolab Inc. (2006-2022) ; U.S. Bancorp (2008-2018).

Mr. Thulin has extensive management, operational, technology, and international business expertise, as demonstrated by a track record of success leading 3M Company. Mr. Thulin possesses broad industry experience drawn from 3M's diverse businesses, commitment to research and strong life sciences division. He also brings valuable insight into driving innovation, based on his experience with new product development and manufacturing. In addition, his previous directorships at other public companies provide him with deep experience on governance issues facing large public companies. Career Highlights 3M Company, global technology company; Executive Chairman (2018-2019); Chairman, President and Chief Executive Officer (2012-2018); President and Chief Executive Officer (2012); Executive Vice President and Chief Operating Officer (2011-2012); Executive Vice President, International Operations (2004-2011) Other Public Directorships Current; None Former; 3M Company (2012-2019); Chevron Corporation (2015-2019).

Ms. Coe has a deep understanding of the digital, media, and technology landscape, as well as global strategy and operations, based on her experience as the Chief Business Officer at YouTube Inc. as well as her experience at Google Inc. At YouTube, Ms. Coe leads all global business operations, business development, and partnerships across product and content licensing and distribution, support operations, and YouTube's monetization, including advertising and subscription revenue. At Google, Ms. Coe served as the President of Google Customer Solutions, overseeing the global ads business for mid-market and small businesses, serving millions of customers and thousands of partners worldwide. She also has extensive marketing and sales expertise from her leadership position at McKinsey and other global marketing consulting firms. Career Highlights: YouTube Inc. ; Chief Business Officer (2022-present) Google Inc. ; President, Google Customer Solutions (2017-2022) ; Vice President, Go-to-Market Vice President, Go-to-Market Operations and Strategy (2012-2017). Other Public Directorships: Current ; None Former ; Whole Foods Market, Inc. (2016-2017).

Ms. Warden has broad experience in operational leadership as Chair, CEO and President of Northrop Grumman Corporation, an innovative company using science, technology, and engineering to create and deliver products and services. Ms. Warden has extensive expertise in strategy, performance, and business development in government and commercial markets, as well as cybersecurity expertise. Prior to joining Northrop Grumman, Ms. Warden held leadership roles at General Dynamics and General Electric. In addition, Ms. Warden is a former chair of the board of the Richmond Federal Reserve Bank. Career Highlights Northrop Grumman Corporation, global security company ; Chair, Chief Executive Officer and President (2019-present) ; President and Chief Operating Officer (2018) ; Corporate Vice President and President, Mission System Sector (2016-2017) ; Corporate Vice President and President, Information Systems Sector (2013-2015) ; Vice President, Cyber Intelligence Division (2011-2012) Other Public Directorships Current ; Northrop Grumman Corporation (2018-present).

Mr. Chirfi Guindo, Senior Vice President, Chief Marketing Officer, Human Health (since July 2022); Prior to that, Executive Vice President, Head of Global Product Strategy and Commercialization, Biogen Inc. (July 2018-July 2022).

On February 5, 2024, the Company announced that Ms. Betty D. Larson will join the Company and assume the role as chief human resources officer, effective at the beginning of April 2024. Business Experience: Executive Vice President and Chief Human Resources Officer (since April 2024); Prior to that, Chief People Officer, GE HealthCare (February 2022-April 2024); Executive Vice President and Chief Human Resources Officer, Becton Dickinson (June 2018-February 2022).

The Company announced that Mr. David R. Maraldo will assume the role as Executive Vice President and President, Merck Manufacturing Division, effective May 1, 2026. Senior Vice President, Human Health Operations (since June 2025), Senior Vice President, Global Biologic Operations (February 2022 - June 2025), Vice President, Large Molecule Commercialization (June 2020 - February 2022)

Mr. Jannie Oosthuizen, Senior Vice President and President Merck U.S. Human Health (since January 2022); Senior Vice President and Head of Global Oncology Commercial (January 2021-December 2021); Senior Vice President and President of MSD K.K. (July 2016-December 2020).

Dalton E. Smart III, Senior Vice President Finance - Global Controller (since December 2023); Vice President, Assistant Controller (September 2023-December 2023); Vice President, Internal Audit (March 2015-September 2023)

Richard R. DeLuca, Jr., September 2011 - Executive Vice President and President, Merck Animal Health, Merck & Co., Inc. - responsible for the Merck Animal Health organization; Prior to September 2011, Mr. DeLuca was Chief Financial Officer, Becton Dickinson Biosciences (a medical technology company) since 2010 and President, Wyeth's Fort Dodge Animal Health division from 2007 to 2010. He also served as Chief Operating Officer, Fort Dodge from 2006 to 2007 and Executive Vice President and Chief Financial Officer from 2002 to 2006.

Mr. David Michael Williams, Executive Vice President, Chief Information and Digital Officer (since August 2020); Acting Chief Information and Digital Officer (December 2019-August 2020).